stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Book value per share
Xenon Pharmaceuticals Inc.'s book value per share at the end of fiscal 2025 was 7.3×, down 24.3% from 9.7× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 12.5×. Over the past ten years it has ranged from 2.0× (fiscal 2017) to 13.9× (fiscal 2023); the current reading is higher than 64% of that period. Xenon Pharmaceuticals Inc. ranks 67th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 7.3× | (24.26%) |
| FY2024 | 9.7× | (30.14%) |
| FY2023 | 13.9× | 16.41% |
| FY2022 | 11.9× | (5.48%) |
| FY2021 | 12.6× | 154.14% |
| FY2020 | 5.0× | 39.91% |
| FY2019 | 3.5× | (33.32%) |
| FY2018 | 5.3× | 166.14% |
| FY2017 | 2.0× | (51.56%) |
| FY2016 | 4.1× | (3.49%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 12.5× | (18.57%) |
| Mar 2026 | 15.3× | 108.66% |
| Dec 2025 | 7.3× | 3.97% |
| Sep 2025 | 7.1× | (12.07%) |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| IRON Disc Medicine, Inc. compare | 16.7× |
| XENE Xenon Pharmaceuticals Inc. | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| TNGX Tango Therapeutics, Inc. compare | 6.8× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| RLAY Relay Therapeutics, Inc. compare | 4.4× |
| ABCL AbCellera Biologics Inc. compare | 2.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Altman Z-score
- The full statement